Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTP-730
- Development stage
- Discontinued
- Lead developer
- Concert Pharmaceuticals
- Modality
- Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
CTP-730 is a deuterium-modified analog of apremilast, designed as a selective phosphodiesterase 4 (PDE4) inhibitor. The incorporation of deuterium into the apremilast molecule aims to improve its pharmacokinetic properties and potentially offer once-daily dosing compared to the original drug. Developed by Concert Pharmaceuticals, CTP-730 was investigated as an anti-inflammatory agent and for potential use in cancer. Phase 1 clinical trials demonstrated that it achieved similar steady-state exposure with once-daily dosing compared to twice-daily dosing of standard apremilast. However, development for both inflammation and cancer indications has been discontinued[1][2][3][4].
- Other names
- Apremilast deuteratedDeuterated apremilast
02
Targets
PDE4 (Phosphodiesterase 4A1)
Beyond the preview
Go deeper on CTP-730.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTP-730.